Researchers Discover How Lithium Works

Despite more than 30 years of widespread use of lithium to control psychiatric disorders, such as bipolar disorder, scientists have been uncertain about how this drug actually works on a molecular level.

However, in a paper published in the January 11th issue of Cell, a Duke Medical Center team has found that lithium may alleviate manic and depressive-like behaviors by interrupting the signaling of a dopamine receptor in the brain. The team was led by Marc G. Caron, Ph.D., James B. Duke Professor in the Department of Cell Biology, Medicine and Neurobiology, and Martin Beaulieu, Ph.D., now at Université Laval.

Over the years, lithium has been shown to act principally on two targets in the brain. It is known to inhibit enzymes that maintain a signaling pathway from the cell membrane. And it inhibits an enzyme called glycogen synthase kinase 3 (GSK-3), which is important in the cell's response to many signaling molecules. But, whether these targets are important for the therapeutic effects of lithium has been unclear.

Caron and Beaulieu previously showed that one of the dopamine receptors in the brain, the D2 receptor, transmits its signal by engaging a pathway involving GSK-3. The D2 receptor regulates this pathway with a signaling complex made up of the receptor and enzymes held together by a protein called beta-arrestin 2.

When placed in a new environment, mice genetically engineered to have an overactive dopamine system typically run around frantically. Similar hyperactivity and mania-like state can be seen in mice treated with amphetamines. Previous research by Caron and Beaulieu had shown that treatment with lithium calms these mice by interfering with the D2 receptor/GSK3 pathway. Caron and his colleagues set out to investigate how lithium produced these effects.

"In humans, lithium alleviates the mood swings and excitability characteristic of bipolar disorder. However, the concentrations at which lithium is clinically effective are usually lower that those necessary to affect the presumed targets like GSK3 in preclinical studies. So there had to be another mechanism," said Caron.

The team focused on whether lithium was acting on the beta-arrestin signaling complex after finding that in another line of genetically engineered mice lacking the gene for the beta-arrestin 2 protein, many of the actions of the D2 receptor were absent.

"We found that lithium destabilizes the signaling complex necessary for the D2 receptor to engage the GSK3 signaling pathway," said Beaulieu, the lead author of the study. In the mice that lack beta-arrestin 2, the researchers found that lithium had no effects on a number of mouse behaviors thought to correlate with symptoms of depression and mania in humans.

"We found that the destabilizing effects of lithium on this signaling complex are observed at concentrations of lithium that are in the range of the clinically effective doses used in the treatment of humans," said Caron, the senior author of the study.

Over the past several years, studies by another contributor to this study, Robert J. Lefkowitz, James B. Duke Professor and HHMI Investigator at Duke, have shown that many other receptorss, similar to D2 receptors, can signal through the formation of complexes organized by the protein beta-arrestin 2.

The researchers propose that targeting these beta-arrestin signaling complexes might be an effective target to control cell signaling. "We feel that this mechanism is a new principle of pharmacology and could lead to drugs for a host of disorders," said Caron.

Source: Duke University Medical Center

Related stories:

'Hub' of fear memory formation identified in brain cells
A protein required for the earliest steps in embryonic development also plays a key role in solidifying fear memories in the brains of adult animals, scientists have revealed. An apparent "hub" for changes in the connections between brain cells, beta-catenin could be a potential target for drugs to enhance or interfere with memory formation.
Researchers find key developmental pathway activates lung stem cells
Researchers from the University of Pennsylvania School of Medicine found that the activation of a molecular pathway important in stem cell and developmental biology leads to an increase in lung stem cells. Harnessing this knowledge could help develop therapies for lung-tissue repair after injury or disease. The investigators published their findings online last week in advance of print publication in Nature Genetics.
Lithium and bone healing
Researchers have described a novel molecular pathway that may have a critical role in bone healing and have suggested that lithium, which affects this pathway, has the potential to improve fracture healing.
Advanced Model of World's Smallest Flying Microrobot from Epson
Seiko Epson Corporation ("Epson") announced that it has successfully developed a lighter and more advanced successor to the uFR, the world's smallest and lightest micro-flying robot. Turning once again to its micromechatronics technology, Epson has redefined the state of the art with its uFR-II micro-flying robot - the world's new lightest and most advanced microrobot, which also features Bluetooth wireless control and independent flight[*2]. The uFR-II will be on display at the Emerging Technology Fair, part of the Future Creation Fair that runs from August 27 to 30 at the Tokyo International Forum.
ZPower claims its silver-zinc batteries last 40% longer than lithium-ion
A company called ZPower has designed batteries with silver- and zinc-based electrodes that it says will offer up to 40% more computer time per charge than today´s lithium-ion batteries. Consumers won´t have to wait long to see if the new batteries live up to the claim, as ZPower plans to release the first silver-zinc battery-powered laptop in 2009.
New material could speed development of hydrogen powered vehicles
Researchers in Greece report design of a new material that almost meets the U.S. Department of Energy (DOE) 2010 goals for hydrogen storage and could help eliminate a key roadblock to practical hydrogen-powered vehicles. Their study on a way of safely storing hydrogen, an explosive gas, is scheduled for the Oct. 8 issue of ACS' Nano Letters.
Electric vehicles spark at Paris car show
Carmarkers rolled out a slew of electric models at the Paris motor show Friday, with a view to filling dealer showrooms by 2012 when new European legislation on curbing emissions kicks in.
The hybrid offensive
(PhysOrg.com) -- Fraunhofer research engineers are busy converting a standard production gasoline-engine car into a hybrid. By doing so, they aim to demonstrate what hybrid technology can do, and prove that it can even be integrated in existing vehicle design concepts.

News discussion:

Medicine & Health news